Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency

Bradley J Monk*, Robert L Coleman, Mansoor Raza Mirza

*Corresponding author for this work
Original languageEnglish
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Volume33
Issue number6
Pages (from-to)1008-1009
Number of pages2
ISSN1048-891X
DOIs
Publication statusPublished - 5 Jun 2023

Keywords

  • Ovarian Cancer
  • Ovarian Neoplasms/drug therapy
  • United States/epidemiology
  • Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
  • Neoplasm Recurrence, Local/drug therapy
  • Humans
  • Carcinoma, Ovarian Epithelial/drug therapy
  • Female
  • United States Food and Drug Administration

Cite this